Irinotecan pharmacogenetics: A finished puzzle?

Journal of Clinical Oncology

Volumn 32, Issue 22, 2014, Pages 2287-2289

  Phelps, Mitch A ^a   Sparreboom, Alex ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DRUG METABOLIZING ENZYME; FIRTECAN; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; OXALIPLATIN;

CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TRANSPORT; EDITORIAL; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; NEUTROPENIA; NEUTROPHIL COUNT; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; NEOPLASMS;

EID: 84905818955     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.3387     Document Type: Editorial

References (25)

1. Innocenti F, Schilsky RL, Ramírez J, et al: Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 32:2328-2334, 2014
2. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998 (Pubitemid 28510873)
3. Marcuello E, Páez D, Paré L, et al: A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. Br J Cancer 105:53-57, 2011
4. Toffoli G, Cecchin E, Gasparini G, et al: Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 28:866-871, 2010
5. Kim KP, Kim HS, Sym SJ, et al: A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 71: 1609-1617, 2013
6. Goetz MP, McKean HA, Reid JM, et al: UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs 31:1559-1567, 2013
7. Satoh T, Ura T, Yamada Y, et al: Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868-1873, 2011
8. Sawyer M, Ratain MJ: Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171-177, 2001 (Pubitemid 32423722)
9. de Jong FA, Mathijssen RH, Xie R, et al: Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res 10:4068-4071, 2004 (Pubitemid 38812483)
10. Mathijssen RH, Verweij J, de Jonge MJ, et al: Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations. J Clin Oncol 20:81-87, 2002 (Pubitemid 34032599)
11. Monahan RA, Dvorak HF, Dvorak AM: Ultrastructural localization of non-specific esterase activity in guinea pig and human monocytes, macrophages, and lymphocytes. Blood 58:1089-1099, 1981 (Pubitemid 12251132)
12. Ogasawara H, Nishio K, Kanzawa F, et al: Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn J Cancer Res 86:124-129, 1995
13. Smith NF, Figg WD, Sparreboom A: Pharmacogenetics of irinotecan metabolism and transport: An update. Toxicol In Vitro 20:163-175, 2006 (Pubitemid 43087700)
14. Cortejoso L, García MI, García-Alfonso P, et al: Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol 71:1463-1472, 2013
15. Goey AK, Mooiman KD, Beijnen JH, et al: Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 39:773-783, 2013
16. Maekawa K, Harakawa N, Yoshimura T, et al: CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 38:2100-2104, 2010
17. Werk AN, Lefeldt S, Bruckmueller H, et al: Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther 95:416-422, 2014
18. Iusuf D, Ludwig M, Elbatsh A, et al: OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice. Mol Cancer Ther 13:492-503, 2014
19. de Jong FA, Kitzen JJ, de Bruijn P, et al: Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer Biol Ther 5:1105-1110, 2006 (Pubitemid 44772222)
20. Kitamura Y, Kusuhara H, Sugiyama Y: Functional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestine. J Pharmacol Exp Ther 332:659-666, 2010
21. Iusuf D, van de Steeg E, Schinkel AH: Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. Clin Pharmacol Ther 92:559-562, 2012
22. Di Paolo A, Bocci G, Polillo M, et al: Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab 12:932-943, 2011
23. Ni W, Ji J, Dai Z, et al: Flavopiridol pharmacogenetics: Clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One 5:e13792, 2010
24. Zimmerman EI, Hu S, Roberts JL, et al: Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19:1458-1466, 2013
25. Nozawa T, Minami H, Sugiura S, et al: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33:434-439, 2005 (Pubitemid 40279945)